Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
$7.23
-5.7%
$10.00
$6.53
$30.60
$63.13M2.89146,614 shs61,808 shs
Palvella Therapeutics stock logo
PVLA
Palvella Therapeutics
$22.94
-3.3%
$23.95
$6.20
$29.27
$253.63M0.168,437 shs48,410 shs
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
$3.01
-0.3%
$2.80
$1.87
$11.40
$262.88M-0.161.53 million shs527,217 shs
2seventy bio, Inc. stock logo
TSVT
2seventy bio
$5.00
$4.97
$2.29
$5.30
$266.15M1.04635,251 shsN/A
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
-5.74%-12.26%-28.27%-51.81%-60.56%
Palvella Therapeutics stock logo
PVLA
Palvella Therapeutics
-3.29%-1.25%-9.65%+22.02%+2,293,999,900.00%
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
-0.33%-4.44%+3.08%-19.95%-49.83%
2seventy bio, Inc. stock logo
TSVT
2seventy bio
0.00%0.00%+0.40%+93.05%+10.86%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
3.3005 of 5 stars
2.93.00.04.62.20.80.0
Palvella Therapeutics stock logo
PVLA
Palvella Therapeutics
3.788 of 5 stars
4.60.00.00.02.84.20.6
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
4.1015 of 5 stars
3.32.00.04.13.72.50.6
2seventy bio, Inc. stock logo
TSVT
2seventy bio
1.4463 of 5 stars
0.94.00.00.03.42.51.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
1.80
Reduce$73.67918.90% Upside
Palvella Therapeutics stock logo
PVLA
Palvella Therapeutics
3.13
Buy$46.29101.77% Upside
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
2.60
Moderate Buy$15.63419.10% Upside
2seventy bio, Inc. stock logo
TSVT
2seventy bio
1.80
Reduce$4.25-15.00% Downside

Current Analyst Ratings Breakdown

Latest MCRB, TSVT, TERN, and PVLA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/16/2025
Palvella Therapeutics stock logo
PVLA
Palvella Therapeutics
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$53.00 ➝ $52.00
5/13/2025
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$26.00 ➝ $15.00
5/10/2025
2seventy bio, Inc. stock logo
TSVT
2seventy bio
Weiss Ratings
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSell (E+) ➝ Sell (D-)
5/8/2025
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Neutral$1.25 ➝ $6.00
4/30/2025
Palvella Therapeutics stock logo
PVLA
Palvella Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$38.00 ➝ $38.00
4/24/2025
2seventy bio, Inc. stock logo
TSVT
2seventy bio
Weiss Ratings
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSell (D-) ➝ Sell (E+)
4/21/2025
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$20.00 ➝ $20.00
4/9/2025
Palvella Therapeutics stock logo
PVLA
Palvella Therapeutics
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$50.00
4/8/2025
2seventy bio, Inc. stock logo
TSVT
2seventy bio
Weiss Ratings
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSell (E+) ➝ Sell (D-)
4/1/2025
Palvella Therapeutics stock logo
PVLA
Palvella Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$38.00 ➝ $38.00
3/26/2025
Palvella Therapeutics stock logo
PVLA
Palvella Therapeutics
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$45.00
(Data available from 5/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
$126.33M0.50N/AN/A($0.35) per share-20.66
Palvella Therapeutics stock logo
PVLA
Palvella Therapeutics
$42.81M5.92N/AN/A$21.66 per share1.06
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
N/AN/AN/AN/A$4.13 per shareN/A
2seventy bio, Inc. stock logo
TSVT
2seventy bio
$48.37M5.50N/AN/A$5.04 per share0.99
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
-$113.72M-$4.60N/AN/AN/AN/AN/A-55.08%8/12/2025 (Estimated)
Palvella Therapeutics stock logo
PVLA
Palvella Therapeutics
-$24.54M-$12.10N/AN/AN/AN/A-80.93%-59.55%8/13/2025 (Estimated)
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
-$90.21M-$1.09N/AN/AN/AN/A-32.76%-31.33%8/4/2025 (Estimated)
2seventy bio, Inc. stock logo
TSVT
2seventy bio
-$217.57M-$0.10N/AN/AN/A-207.25%-53.65%-23.67%8/6/2025 (Estimated)

Latest MCRB, TSVT, TERN, and PVLA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/15/2025Q1 2025
Palvella Therapeutics stock logo
PVLA
Palvella Therapeutics
-$3.40-$0.74+$2.66-$0.74N/AN/A
5/8/2025Q1 2025
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
-$0.29-$0.26+$0.03-$0.26N/AN/A
5/7/2025Q1 2025
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
-$0.67-$2.24-$1.57$3.75$10.00 millionN/A
5/7/2025Q1 2025
2seventy bio, Inc. stock logo
TSVT
2seventy bio
-$0.10$0.01+$0.11$0.01$13.96 million$22.94 million
3/25/2025Q4 2024
2seventy bio, Inc. stock logo
TSVT
2seventy bio
-$0.23-$0.31-$0.08-$0.37$12.84 million$2.93 million
3/20/2025Q4 2024
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
-$0.30-$0.24+$0.06-$0.24N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
N/AN/AN/AN/AN/A
Palvella Therapeutics stock logo
PVLA
Palvella Therapeutics
N/AN/AN/AN/AN/A
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
N/AN/AN/AN/AN/A
2seventy bio, Inc. stock logo
TSVT
2seventy bio
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
N/A
1.12
1.12
Palvella Therapeutics stock logo
PVLA
Palvella Therapeutics
N/A
4.82
4.82
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
N/A
32.99
32.99
2seventy bio, Inc. stock logo
TSVT
2seventy bio
N/A
4.95
4.95

Institutional Ownership

CompanyInstitutional Ownership
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
59.34%
Palvella Therapeutics stock logo
PVLA
Palvella Therapeutics
40.11%
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
98.26%
2seventy bio, Inc. stock logo
TSVT
2seventy bio
93.90%

Insider Ownership

CompanyInsider Ownership
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
4.70%
Palvella Therapeutics stock logo
PVLA
Palvella Therapeutics
20.50%
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
1.50%
2seventy bio, Inc. stock logo
TSVT
2seventy bio
7.20%
CompanyEmployeesShares OutstandingFree FloatOptionable
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
3308.73 million162.03 millionOptionable
Palvella Therapeutics stock logo
PVLA
Palvella Therapeutics
N/A11.06 million10.50 millionN/A
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
4087.34 million72.11 millionNot Optionable
2seventy bio, Inc. stock logo
TSVT
2seventy bio
44053.23 million47.87 millionOptionable

Recent News About These Companies

2seventy Bio reports Q4 EPS (37c) vs ($1.11) last year
2seventy Bio price target lowered to $5 from $6 at Morgan Stanley

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Seres Therapeutics stock logo

Seres Therapeutics NASDAQ:MCRB

$7.23 -0.44 (-5.74%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$7.61 +0.38 (+5.26%)
As of 05/27/2025 07:23 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Seres Therapeutics, Inc., a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The company's lead product candidate is VOWST, an oral microbiome therapeutic that has completed Phase III clinical trial for the treatment of recurrent Clostridioides difficile infection. Its product pipeline also includes SER-155, an investigational oral fermented microbiome therapeutic which is in Phase 1b clinical trials for the treatment of gastrointestinal infections, bacteremia, and graft versus host disease in immunocompromised patients including patients receiving allogeneic hematopoietic stem cell transplantation. In addition, the company engages in the development of SER-287 which is in Phase 2b and SER-301 that is in Phase 1b to treat ulcerative colitis. Further, it has license Agreement with NHSc Rx License GmbH for the therapeutic products based on the microbiome technology, which includes VOWST product candidate, which is developed for the treatment of CDI and recurrent CDI; and collaboration license agreement with Société des Produits Nestlé S.A. (Nestlé) for the development and commercialization of certain product candidates for the treatment and management of CDI and inflammatory bowel disease including UC and Crohn's disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

Palvella Therapeutics stock logo

Palvella Therapeutics NASDAQ:PVLA

$22.94 -0.78 (-3.29%)
As of 05/27/2025 04:00 PM Eastern

Palvella Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc., formerly known as Pieris Pharmaceuticals Inc., is based in WAYNE, Pa.

Terns Pharmaceuticals stock logo

Terns Pharmaceuticals NASDAQ:TERN

$3.01 -0.01 (-0.33%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$3.02 +0.02 (+0.50%)
As of 05/27/2025 05:23 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of MASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.

2seventy bio stock logo

2seventy bio NASDAQ:TSVT

$5.00 0.00 (0.00%)
As of 05/13/2025

2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma. It has a collaboration arrangement with Bristol Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.